Merck KGaA – Talk Bio

Kai Beckmann Appointed as Successor to Merck KGaA CEO Belén Garijo, Effective May 2026

1 month ago talkbio0Tagged Belén Garijo, business career, CEO, Corporate, Electronic, Executive Board, governance, Health Care Sector, Kai Beckmann, Leadership Transition, Merck KGaA, strategic transformation, succession

Merck KGaA; Kai Beckmann; Belén Garijo; CEO Succession; Electronics Business; Executive Board; Leadership Transition; Healthcare sector; Corporate governance; Strategic transformation

Merck KGaA and Skyhawk Therapeutics Launch $2B RNA-Targeting Neurology Collaboration

2 months ago talkbio0Tagged Billion Collaboration, Drug Development, Merck KGaA, milestone payments, nervous system disorder, RNA-targeting, royalties, Skyhawk, SkySTAR platform

Merck KGaA; Skyhawk Therapeutics; RNA-targeting; SkySTAR platform; neurological disorders; $2 billion collaboration; drug development; milestone payments; royalties

Merck KGaA Forms $2 Billion Neurological Disease Pact with Skyhawk Therapeutics

2 months ago talkbio0Tagged Drug Discovery, Merck KGaA, milestone payments, Neurological diseases, RNA Splicing, Skyhawk, SkySTAR platform, strategic collaboration

Merck KGaA; Skyhawk Therapeutics; neurological diseases; RNA splicing; SkySTAR platform; drug discovery; strategic collaboration; milestone payments

Merck KGaA springs back into M&A game with $3.9B buyout of Pfizer spinout SpringWorks

6 months ago talkbio0Tagged disease treatments, Fibromatosis, Aggressive, Gomekli, KGaA, Merck KGaA, Neurofibromatosis 1, Ogsiveo, Pfizer, Pfizer/, pharmaceutical acquisition, SpringWorks

Pharmaceutical acquisition, rare disease treatments, Merck KGaA, SpringWorks Therapeutics, Ogsiveo, Gomekli, desmoid tumors, neurofibromatosis type 1 (NF1), Pfizer spinout